What science
can do
Annual Report & Form 20-F
Information 2017
Overview
本年度报告提供了澳门在线赌城娱乐业务的顶级信息，以及澳门第一赌城在线娱乐在2017年在推动科学边界以提供改变生活的药物方面取得的进展.
委员会的基本职责之一是制定澳门第一赌城在线娱乐的战略和监测实现澳门第一赌城在线娱乐目标的进展情况, so that we bring our science to patients, create value for society, and reward you, our shareholders.
2017年对澳门在线赌城娱乐来说是决定性的一年. 2018年将同样重要，因为澳门第一赌城在线娱乐将努力发挥澳门第一赌城在线娱乐药物的全部潜力，并确保澳门第一赌城在线娱乐将澳门第一赌城在线娱乐的科学成果提供给世界各地的患者.
In 2017, 澳门第一赌城在线娱乐的财务业绩反映了几种新药的上市, the strong performance of our Growth Platforms and the continued impact from patent expiries; most notably for Crestor and Seroquel XR in the US.
Key Highlights
Total Revenue
$22.5bn
Net cash flow from operating activities
$3.6bn
Reported operating profit
$3.7bn
Core operating profit
$6.9bn
Reported EPS
$2.37
Core EPS
$4.28
At a Glance
澳门第一赌城在线娱乐是一家全球性的澳门第一赌城在线娱乐企业，通过创新的科学和卓越的开发和商业化，为患者提供药物.
Product Sales
$20,152m
2016: $21,319m
2015: $23,641m
By therapeutic area
-01.png/jcr:content/renditions/cq5dam.web.320.AZ_Portfolio_of_specialty_and_primary_care_products_(product_sales)-01.png)
By geography
-01.png/jcr:content/renditions/cq5dam.web.320.AZ_Global_commercial_presence_with_strength_in_Emerging_Markets_(product_sales)-01.png)
61,100
100%
84%
Dividend per Ordinary Share
for 2017
1st interim dividend
$0.90
Pence: 68.9
SEK: 7.40
Payment date: 11 September 2017
2nd interim dividend
$1.90
Pence: 133.6
SEK: 14.97
Payment date: 19 March 2018
Total
$2.80
Pence: 202.5
SEK: 22.37
Strategy
澳门第一赌城在线娱乐在2013年宣布了恢复增长的战略. 2015年，澳门第一赌城在线娱乐从旅程的第一阶段开始，专注于重建澳门第一赌城在线娱乐的管道. 第二阶段是推动增长平台向前发展的关键阶段, 继续推出新药并使患者能够获得. As we look ahead to 2020 and beyond, 持续的投资将使澳门第一赌城在线娱乐回到可持续增长的轨道上，与澳门第一赌城在线娱乐的目标保持一致.
2017年，澳门第一赌城在线娱乐的战略重点集中在以下三个支柱下.
-
Achieve Scientific Leadership
澳门第一赌城在线娱乐将科学研究重点放在三个治疗领域，并加快研发进程. We are also transforming our way of working.
-
Return to Growth
澳门第一赌城在线娱乐正专注于澳门第一赌城在线娱乐的增长平台，并通过专业护理转变业务, devices and biologic medicines. 有针对性的业务发展加强了澳门第一赌城在线娱乐的努力.
-
Be a Great Place to Work
澳门第一赌城在线娱乐正在发展澳门第一赌城在线娱乐的文化，简化澳门第一赌城在线娱乐的业务. We want to attract and retain the best talent. We also want to do business sustainably.
Therapy Area Highlights
澳门第一赌城在线娱乐已经转变了澳门第一赌城在线娱乐的药物组合，专注于三个治疗领域:肿瘤，心血管 & 代谢疾病(CVMD)和呼吸疾病，同时选择性地活跃在其他疾病领域.
Oncology
$4,024m
Product Sales (2016: $3,383m, 2015: $2,825m)
Highlights
- Tagrisso 销售额增长126% (CER增长126%)，并在60多个市场获得批准
- Iressa sales of $528 million, up 3% (3% at CER); Lynparza sales of $297 million, up 36% (35% at CER)
- Imfinzi 5月在美国推出，销售额为1900万美元; Calquence 去年10月在美国推出，销售额为300万美元
Cardiovascular & Metabolic Diseases
$7,266m
Product Sales (2016: $8,116m, 2015: $9,489m)
Highlights
- Brilinta sales of $1,079 million, up 29% (29% at CER) and Forxiga sales of $1,074 million, up 29% (28% at CER)
- Sales of Onglyza were down by 15% (16% at CER) to $611 million
- Legacy sales: Crestor down 30% (30% at CER) to $2,365 million
Respiratory
$4,706m
Product Sales (2016: $4,753m, 2015: $4,987m)
Highlights
- Symbicort sales of $2,803 million, down 6% (6% at CER)
- Sales of Pulmicort up 11% (12% at CER) at $1,176 million
- Fasenra approved in the US in November
Other Disease Areas
$4,156m
Product Sales (2016: $5,067m, 2015: $6,340m)
Highlights
- Nexium sales down 4% (3% at CER) to $1,952 million
- Sales of Synagis up 1% (1% at CER) to $687 million
- Seroquel XR sales of $332 million, down 55% (55% at CER)
- FluMist/Fluenz sales of $78 million, down 25% (28% at CER)
